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ABSTRACT
Objectives: To evaluate the safety and efficacy of 5-year,
long-term tocilizumab monotherapy for patients with
rheumatoid arthritis.
Methods: In an open-label, long-term extension trial
following an initial 3-month randomised phase II trial, 143
of the 163 patients who participated in the initial blinded
study received tocilizumab monotherapy (8 mg/kg) every
4 weeks. Concomitant therapy with non-steroidal anti-
inflammatory drugs and/or oral prednisolone (10 mg daily
maximum) was permitted. All patients were evaluated
with American College of Rheumatology (ACR) improve-
ment criteria, disease activity score (DAS) in 28 joints,
and the European League Against Rheumatism response,
as well as for safety issues.
Results: 143 patients were enrolled in the open-label,
long-term extension trial and 94 (66%) patients had
completed 5 years as of March 2007. 32 patients (22%)
withdrew from the study due to adverse events and one
patient (0.7%) due to unsatisfactory response. 14 patients
withdrew because of the patient’s request or other
reasons. The serious adverse event rate was 27.5 events
per 100 patient-years, with 5.7 serious infections per 100
patient-years, based on a total tocilizumab exposure of
612 patient-years. Of the 88 patients receiving corticos-
teroids at baseline, 78 (88.6%) were able to decrease
their corticosteroid dose and 28 (31.8%) discontinued
corticosteroids. At 5 years, 79/94 (84.0%), 65/94 (69.1%)
and 41/94 (43.6%) of the patients achieved ACR20,
ACR50, and ACR70 improvement criteria, respectively.
Remission defined as DAS28 less than 2.6 was achieved
in 52/94 (55.3%) of the patients.
Conclusion: In this 5-year extension study, tocilizumab
demonstrated sustained long-term efficacy and a
generally good safety profile.
Rheumatoid arthritis (RA) is a chronic inflamma-
tory disease characterised by persistent synovitis
and progressive joint damage.
1 Although the causes
of RA are not fully understood, constitutive
overproduction of IL-6, a multifunctional cytokine
that regulates the immune response, inflammatory
reaction and bone metabolism, is thought to play a
major pathological role in RA.
2
Tocilizumab is a humanised anti-human IL-6
receptor monoclonal antibody,
2 which has been
demonstrated to improve the signs and symptoms
of RA
3–9 and prevent radiographic progression
10 in
previous clinical trials. Those controlled trials
provided evidence for a rapid reduction in disease
activity in response to tocilizumab in patients with
active RA as measured by American College of
Rheumatology (ACR) responses, disease activity
scores (DAS) and a modified health assessment
questionnaire (MHAQ).
5–9 The efficacy was dose
related and 8 mg/kg tocilizumab provided a
marked clinical benefit. The success in the treat-
ment of patients with RA using tocilizumab
confirmed that IL-6 plays an important pathologi-
cal role in RA, and further studies were therefore
required to determine the long-term safety and
efficacy of tocilizumab treatment. We report here
the safety and efficacy of tocilizumab in a 5-year
long-term extension study.
METHODS
Patients
This study was registered with http://www.
clinicaltrials.gov (NCT00144651). The study pro-
tocol was approved by the Ministry of Health,
Labor and Welfare of Japan and by the ethical
committee of each institute, and patients gave
their written informed consent.
The eligibility criteria and the study design of
the initial 12-week, randomised, double-blind,
placebo controlled study have been reported
previously.
5 Briefly, eligible patients were 20 years
of age or older and fulfilled the 1987 criteria for RA
of the American Rheumatism Association
11 with a
disease history of longer than 6 months. All
subjects had been insufficient responders to treat-
ment with at least one disease-modifying anti-
rheumatic drug (DMARD) or immunosuppressant.
Patients had active disease at the time of enroll-
ment into the initial controlled trial, as defined by
the presence of six or more swollen joints, six or
more tender joints and one of the following two
criteria: a Westergren erythrocyte sedimentation
rate (ESR) of at least 30 mm/h or a C-reactive
protein (CRP) level of more than 1.0 mg/dl.
Patients receiving prednisolone (10 mg daily max-
imum) and/or non-steroidal anti-inflammatory
drugs (NSAID) were eligible if the dose had not
increased during the washout period of 1 month.
Doses of both medications remained stable during
the blinded study period of 12 weeks. Patients who
had received tocilizumab or placebo twice or more
were given the opportunity to receive tocilizumab
in this open-label extension trial.
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maximum) and one NSAID was permitted. Sexually active
premenopausal women were required to have a negative urine
pregnancy test at entry and to use effective contraception
during the study period.
Treatment
Patients were randomly assigned to receive either placebo, or 4
or 8 mg/kg body weight of tocilizumab every 4 weeks in the
initial blinded 12-week trial. In the first 12 weeks of the open-
label extension study, patients received 8 mg/kg tocilizumab
every 4 weeks and thereafter dose reduction and treatment
interval changes (minimum 2 weeks) were allowed.
Efficacy assessments
Disease activity was assessed at baseline and at every visit
during the initial blinded trial and the first 12 weeks of the
extension study, and thereafter every 3 months. All patients
were evaluated with ACR improvement criteria, DAS28 and the
European League Against Rheumatism response. The DAS28
was calculated using the ESR. Clinical assessments included the
following: complete counts of swollen and tender joints (49
joints evaluated; cervical spine and hips evaluated only for
tenderness); physician’s and patient’s global assessment of
disease status, on a visual-analogue scale from 0 (asymptomatic)
to 100 (severe symptoms); patient’s assessment of pain on a
scale from 0 (no pain) to 100 (severe pain); functional disability
measured with a MHAQ; ESR and CRP levels.
12 Treatment time
was calculated beginning with the first infusion of tocilizumab,
excluding the time receiving placebo.
Safety assessments
Safety was assessed for all patients who received at least one
dose of tocilizumab in the extension study. Serious adverse
events (SAE) were defined as events that were fatal or life-
threatening, leading to permanent or significant disability or
incapacity, a congenital anomaly or birth defect, or requiring
prolonged inpatient hospitalisation. Adverse events were
classified using the Medical Dictionary for Drug Regulatory
Affairs (MedRA version 8.0).
Statistical analysis
Patients who had remained in the study and had completed visit
reports were analysed. No imputation was used for missing
data. A paired t test was employed to detect statistically
significant differences in disease activity and functional out-
comes from baseline. Statistical analyses were performed with
SAS version 8.2 TS2M0. The continuation rate, defined as the
cumulative percentage of patients still receiving medication,
was analysed using the Kaplan–Meier method. Analysis of
adverse events was performed with the person-year method.
RESULTS
Characteristics of the patients
A total of 143 patients was enrolled in the open-label, long-term
extension trial; 108 patients (76%) had completed 3 years and
94 patients (66%) had completed 5 years, as of March 2007
(fig 1). The median duration of treatment with tocilizumab was
66.7 months (range 0.95–73.2).
Thirty-two patients (22%) withdrew due to adverse events.
Only one patient (0.7%) withdrew due to unsatisfactory
response. Other reasons for withdrawals were as follows: eight
for patient’s personal requests; one for the emergence of anti-
tocilizumab antibodies and five for other reasons.
The baseline demographic and clinical data are summarised in
table 1. The patients’ mean age was 54 years and the mean
disease duration was 9.9 years. Patients had very active disease
at baseline, in terms of the increased number of tender and
swollen joint counts and elevated ESR of 68.7 mm/h and CRP
levels of 4.7 mg/dl. Furthermore, the baseline DAS28 was 6.7.
Safety
A total of 148 SAE was reported in 77 patients (53.8%) for an
overall rate of 27.5 events per 100 patient-years. Table 2 shows
SAE (occurring in at least 1% of patients). Joint surgery related
to RA was the most common SAE and occurred in 20 patients
(14.0%). In addition, a variety of musculoskeletal disorders was
reported as SAE, which were classified as not related to
tocilizumab.
Serious infections were reported in 25 patients (17.5%) at a
rate of 5.7 events per 100 patient-years. The most frequently
reported infections were as follows: pneumonia (nine patients,
1.5 events per 100 patient-years); herpes zoster (seven patients,
1.1 events per 100 patient-years); acute bronchitis (five patients,
Figure 1 Kaplan–Meier estimate of the probability of the patients
remaining on study. Treatment time was calculated beginning with the
first infusion of tocilizumab at any dose, excluding the time receiving
placebo.
Table 1 Demographics and baseline clinical
characteristics of patients with RA who received
tocilizumab at any time during the blinded period or open-
label extension of the tocilizumab study
Tocilizumab
(n = 143)
Demographics
Age, years (SD) 54.3 (11.1)
No of men/no of women 34/109
Clinical characteristics
RA duration, years (SD) 9.9 (8.4)
No of failed DMARD, mean (range) 4.5 (1–11)
Functional class,* I/II/III/IV 10/93/40/0
RA stage,* I/II/III/IV 3/34/56/50
Tender joint count, 0–49 scale (SD) 20.3 (10.3)
Swollen joint count, 0–46 scale (SD) 14.5 (8.7)
ESR, mm/h (SD) 68.7 (29.9)
CRP, mg/dl (SD) 4.7 (3.3)
DAS28 (SD) 6.7 (1.0)
Values are mean (SD) unless stated otherwise. The data were
calculated from the baseline of the double-blind trial (4 mg/kg group,
8 mg/kg group) and from the extension trial (placebo group).
*Rheumatoid arthritis (RA) functional status determined by
American College of Rheumatology criteria. RA stage determined by
Steinbrocker’s criteria. CRP, C-reactive protein; DAS28, disease
activity score in 28 joints; DMARD, disease-modifying antirheumatic
drugs; ESR, erythrocyte sedimentation rate.
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patients, 0.5 events per 100 patient-years).
Four malignancies were reported in four patients (2.8%; 0.7
events per 100 patient-years). The types of malignancies were
bladder cancer, breast cancer, large intestine carcinoma and
intraductal papilloma.
Temporary prolongation of treatment intervals with tocili-
zumab was observed throughout the study. Although 163
events of prolonged intervals of 8 weeks or more occurred, the
majority of the prolongation of intervals was due to transition
from the randomised study to the extension study (median
interval of the transition was 10.1 weeks). No particular adverse
events were reported when tocilizumab was re-administered
except for one patient with a severe infusion reaction. The
patient had received 4 mg/kg tocilizumab in the initial 3-month
trial, and IgE anti-tocilizumab antibodies appeared at the second
infusion of the extension trial. Two more patients were positive
for anti-tocilizumab antibodies, when tocilizumab was not
detectable in their blood. No adverse event was reported related
to the anti-tocilizumab antibodies.
Mean non-fasting total blood cholesterol increased after
treatment initiation and stabilised (mean values 185 mg/dl at
baseline; 220 mg/dl at 12 months; 214 mg/dl at 60 months;
fig 2A). A total of 112 patients experienced total cholesterol
abnormalities at at least one point and 15 patients had abnormal
values at baseline. Thirty-nine patients (34.8%) were treated with
statins, including two patients who had started statin treatment
before the trial. There were no cardiovascular SAE related to
tocilizumab except for ischaemic heart disease reported in one
patient whose total blood cholesterol increased from 168 mg/dl at
baseline to 227 mg/dl without statin treatment. The patient also
had the risk factor of diabetes mellitus.
Mean neutrophil counts decreased but remained within the
normal range (fig 2B). Grade 2 neutropenia was observed in 17
patients and grade 3 in nine patients. All the events were
transient, and no patients experienced febrile neutropenia or
withdrew as a result of neutropenia.
Mean aspartate aminotransferase (AST) and alanine amino-
transferase (ALT) increased slightly, but remained roughly within
the normal ranges (fig 2C). Grade 2 or higher increases in AST and
ALT occurred in nine (6.3%) and 14 (9.8%) of 143 patients,
respectively, during the study, but most were transient and
resolved without any particular treatment. No serious liver
disorders, such as fulminant hepatitis, were seen during this study.
Efficacy
The response rate according to the ACR improvement criteria
increased during the initial year and remained constant
throughout the study period (fig 3A). At 5 years, 79 (84.0%),
65 (69.1%) and 41 (43.6%) of 94 patients met ACR20, ACR50
and ACR70, respectively. These response rates analysed with
the last observation carried forward were 77.3%, 58.9% and
37.6%, respectively.
Tocilizumab treatment significantly improved all measures,
including tender joint counts, swollen joint counts (fig 3B), CRP
levels (fig 3C), MHAQ score (fig 3D) and DAS28 score (fig 3E),
and the efficacy was sustained throughout the 5-year treat-
ment. The percentage of patients who achieved clinical
remission defined as DAS28 less than 2.6
13 14 was 55.3% (52/
94) at 5 years. Most patients exhibited anaemia at baseline and
the mean haemoglobin level was 11.3 mg/dl (SD 1.4).
Tocilizumab treatment significantly improved anaemia in these
patients, and the mean haemoglobin level was increased to
13.2 mg/dl (SD 1.5) at year 5 (fig 3F).
Table 2 Serious adverse events observed in at least 1%
of patients
SAE No (%)
Any SAE 77 (53.8)
Joint surgery 20 (14.0)
Pneumonia 9 (6.3)
Herpes zoster 7 (4.9)
Tendon rupture 5 (3.5)
Humerus fracture 4 (2.8)
Spinal osteoarthritis 3 (2.1)
Femoral neck fracture 3 (2.1)
Joint dislocation 2 (1.4)
Back pain 2 (1.4)
Lumbar spinal stenosis 2 (1.4)
Bronchitis acute 2 (1.4)
Pyelonephritis 2 (1.4)
Brain stem infarction 2 (1.4)
Cataract 2 (1.4)
Pneumothorax 2 (1.4)
Liver function abnormality 2 (1.4)
SAE, serious adverse event.
Figure 2 Change in serum total cholesterol, high-density lipoprotein
(HDL) cholesterol, neutrophil counts, aspartate aminotransferase (AST)
and alanine aminotransferase (ALT). Values are means. Bars indicate SD.
BL, baseline.
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than5 yearshadreceivedcorticosteroidswhentheybegantheinitial
study. After 5 years of tocilizumab treatment, 78 of 88 (88.6%) had
been able to decrease their corticosteroid dose and 28 of 88 (31.8%)
had discontinued corticosteroids. The mean dose of corticosteroids
for these patients decreased from 6.9 mg/day (median 7.5 mg/day)
to 2.4 mg/day (median 2.0 mg/day) at 5 years.
DISCUSSION
The STREAM study is the first study demonstrating the long-
term safety and efficacy of tocilizumab monotherapy. This open-
label extension trial of tocilizumab demonstrated a sustained
good efficacy and a generally good safety profile over 5 years. The
high retention rate at 5 years indeed indicates the favourable
efficacy and safety profile. In particular, only one of 143 patients
withdrewasa resultof anunsatisfactoryresponse,indicating that
no general loss of response occurred during long-term treatment.
ACR responses and improvements in DAS28 scores and
individual components of the ACR core set were all sustained
duringthelong-termtreatmentwithtocilizumabmonotherapy.At
5 years, approximately half of patients had achieved ACR70 and
morethanhalfofpatientshadachievedclinicalremissiondefinedas
a DAS28 of less than 2.6, although this study was open labelled.
Tocilizumab monotherapy markedly improved inflammation
markers such as CRP and ESR and improvements were
sustained throughout the study. Haemoglobin levels were also
improved. It is well documented that hepcidin plays a key role
in anaemia of chronic inflammatory diseases. IL-6 induces the
secretion of hepcidin, an iron regulatory peptide hormone that
is produced in the liver and that negatively regulates the
absorption of intestinal iron and iron recycling by macro-
phages.
15 This increase in haemoglobin levels is expected to
contribute to the improvement in patients’ quality of life.
A steroid-sparing effect was another benefit of tocilizumab
therapy for RA patients. As the use of corticosteroids is often
associated with adverse events such as infection or steroid-
induced osteoporosis, this also contributes to the improvement
in patients’ quality of life from the safety point of view.
A major objective of this study was to evaluate long-term
safety. Long-term treatment with tocilizumab was well tolerated.
Most of the adverse events were mild and acceptable compared
withthebenefitprovided.Therateofseriousinfectionsof5.7/100
patient-yearsafter612patient-yearsoftreatmentwascomparable
to that reported with tumour necrosis factor (TNF) antago-
nists.
16 17 There was no systemic opportunistic infection or
tuberculosis in this study. At least two patients with a history
of tuberculosis were treated with tocilizumab because this study
did not exclude patients who had a history of tuberculosis.
Neither had any recurrence nor exacerbation of tuberculosis
without the prophylactic use of antituberculosis drugs. However,
two cases of tuberculosis were reported in another study (two
cases in 1891 patient-years in Japan),
18 and we should therefore
follow patients carefully during tocilizumab treatment.
Four malignancies were reported in four patients. Yamanaka et
al
19 reported a comparison of the incidence of malignancies in the
following three populations: (1) tocilizumab cohort: all clinical
trials(including thistrial)of tocilizumab inactiveRA patients;(2)
IORRA cohort: an observational cohort of RA patients in the
Institute of Rheumatology, Tokyo Women’s Medical University
and (3) a Japanese population database: cancer incidence in Japan
Figure 3 Percentage of responders
according to the American College of
Rheumatology improvement criteria and
the disease activity score in 28 joints
(DAS28) as well as the mean change in
modified health assessment questionnaire
(MHAQ) scores, number of tender joints,
number of swollen joints, C-reactive
protein (CRP) and haemoglobin. BL,
baseline.
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Japan supported by the Japanese Ministry of Health, Labour and
Welfare. The incidence of malignancies in the patients receiving
tocilizumab was almost equivalent to that in the observational
cohort of RA patients or the Japanese population data. Further
study will be required to evaluate whether tocilizumab treatment
might influence the incidence of malignancies using a much larger
population of RA patients treated with tocilizumab.
Throughout long-term treatment, a serious infusion reaction
was observed in only one patient who received 4 mg/kg
tocilizumab in the initial double-blind trial and developed IgE
anti-tocilizumab antibodies. Maini et al
6 reported that anaphy-
laxis and anaphylactoid reactions occurred only at low doses of
tocilizumab in the absence of methotrexate. Therefore, initial
treatment with a relatively low dose (4 mg/kg) of tocilizumab
without methotrexate may induce anti-tocilizumab antibodies.
Increases in total cholesterol, high-density lipoprotein choles-
terol and triglycerides were observed in the initial controlled
study. In this extension study, however, they did not continue
increasing. Furthermore, the atherogenic index, calculated by
(total cholesterol–high-density lipoprotein cholesterol)/high-den-
sity lipoprotein cholesterol, was stable throughout the 5-year
treatment. Therefore, an increase in total cholesterol does not
always mean an increased risk of cardiovascular disease. As IL-6 is
thought to play a causative role in atherosclerosis, IL-6 blockade
may decrease the incidence of cardiovascular events, as observed
with anti-TNF therapy.
20 Further investigation will be required to
evaluate whether tocilizumab might increase the risk of develop-
ing ischaemic heart disease. At present, we should introduce
treatment according to the guideline for cholesterol management.
Neutropenia was also reported, as seen in previous studies,
4–7 9
but the incidence was less frequent than that observed in
combination with methotrexate therapy.
679This may be an
advantage of tocilizumab monotherapy.
Although it has been established that TNF inhibitors should
be given with methotrexate for maximal efficacy,
21 22 this study
indicated that tocilizumab monotherapy offered a good safety
profile and sustained efficacy throughout long-term treatment.
Therefore, tocilizumab has considerable clinical benefit for
patients who do not tolerate methotrexate. Short-term safety
and efficacy studies of tocilizumab in combination with
methotrexate or DMARD have been reported,
6–9 but further
studies are required to determine long-term safety and efficacy.
In conclusion, this study clearly demonstrates excellent long-
term efficacy and generally good safety of tocilizumab mono-
therapy in active RA patients.
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